Product data
- Strength
- 5 mg
- Dosage form
- Tablet
- Dosage-form group
- Oral solid
- Therapeutic area
- Antihypertensive
- Market
- EU
- Exclusivity signed
- UK
- Status
- Dossier target · Mar 2027
- Development status
- Validation batch completed; pivotal bio planned Jul 2026
- Portfolio
- Generic dossier
Start a conversation
Where does your programme stand?
Tell us the molecule, the dosage form and the market you are filing in. A programme lead will read it and reply with what we would do next.
Business enquiries: vasanthi@kmshc.com · +91 97898 75194V-23